CCL27 and myeloid sarcoma: To investigate the impacts of CladT on peripheral ILC in MS patients (Supplementary Tables S1, S2), we established a 43-parameter CyTOF panel (Supplementary Table S4), which allowed us to differentiate ILC subtypes in PBMC from MS patients at baseline (prior), as well as 2 (2M) and 6 months (6M) following the onset of CladT treatment (Supplementary Tables S2, S3).